

**MARKSANS PHARMA LIMITED**

Read Office: 11th Floor, Lotus Business Park Off. New Link Road, Andheri (West), Mumbai-400053

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2013

**PART 1**

(₹ in Lakhs)

Sr. No.	PARTICULARS	3 MONTHS ENDED				ended Previous Year
		30.9.2013 (UNAUDITED)	30.06.2013 (UNAUDITED)	30.9.2012 (UNAUDITED)	30.9.2013 (UNAUDITED)	
1	Income					
a)	Net Sales/ Income from Operations (Net of excise duty)	7,851.37	7,202.09	4,672.64	15,053.45	19,229.70
b)	Other Operating Income	-	270.38	356.17	270.38	417.18
	<b>Total Income from operations (net)</b>	<b>7,851.37</b>	<b>7,472.47</b>	<b>5,028.81</b>	<b>15,323.83</b>	<b>19,646.88</b>
2	Expenses					
a)	Cost of Material Consumed	3,245.68	2,463.49	1,914.72	5,709.17	3,383.67
b)	Purchase of Stock - in- trade	674.01	782.11	341.82	1,456.12	654.74
c)	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(45.23)	155.79	(0.32)	110.56	(2.81)
d)	Employee benefits expense	478.42	468.06	352.38	946.48	705.80
e)	Depreciation and amortisation expense	223.97	220.46	218.06	444.43	432.63
f)	Other expenses	1,047.71	908.86	536.20	1,956.57	3,741.59
	<b>Total Expenses</b>	<b>5,624.56</b>	<b>4,998.77</b>	<b>3,362.86</b>	<b>10,623.33</b>	<b>15,673.14</b>
3	Profit/(Loss) from operations before other Income, finance costs and exceptional items (1-2)	2,226.81	2,473.70	1,665.95	4,700.50	(63.54)
4	Other Income	-	-	-	-	-
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	2,226.81	2,473.70	1,665.95	4,700.50	(63.54)
6	Finance cost	254.12	752.91	226.13	1,007.03	469.47
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	1,972.69	1,720.79	1,439.82	3,693.47	(533.01)
8	Exceptional items	-	-	-	-	-
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	1,972.69	1,720.79	1,439.82	3,693.47	(533.01)
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	193.04	41.96	1,439.82	236.00	(997.77)
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	1,779.65	1,678.83	1,439.82	3,458.47	(533.01)
12	Less: Extraordinary item	-	-	-	-	-
13	Net Profit/ (Loss) for the period (11-12)	1,779.65	1,678.83	1,439.82	3,458.47	(533.01)
14	Paid up Equity Share Capital (Face Value Re. 1 each)	3,853.07	3,853.07	3,678.07	3,853.07	3,853.07
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	-	-
16 a)	Earnings Per Share (before extraordinary items Rs.) - Basic	0.46	0.44	0.39	0.90	(0.14)
	- Diluted	0.46	0.44	0.37	0.90	(0.14)
b)	Earnings Per Share(after extraordinary items- Rs.) - Basic	0.46	0.44	0.39	0.90	(0.14)
	- Diluted	0.46	0.44	0.37	0.90	(0.14)
<b>PART 2</b>						
<b>A PARTICULARS OF SHAREHOLDING</b>						
1	Public Shareholding:					
	- Number of Shares	187,815,471	187,999,472	189,824,114	187,815,471	188,634,244
	- Percentage of Holding	48.75%	48.79%	51.61%	48.75%	48.96%
2	Promoters and Promoter group Shareholdings	197,491,733	197,307,732	177,983,090	197,491,733	196,672,960
a)	Pledged/Encumbered					
	- Number of Shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A	N/A
b)	Non-encumbered					
	- Number of Shares	197,491,733	197,307,732	177,983,090	197,491,733	196,672,960
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%
	- Percentage of Holding (as a % of the total share capital of the Company)	51.25%	51.21%	48.39%	51.25%	51.04%



B/ INVESTOR COMPLAINTS	3 MONTHS ENDED
	30.9.2013
Pending at the beginning of the quarter	Nil
Received during the quarter	2
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	Nil

**Notes:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31.10.2013.
- The Company has published its consolidated financial statements separately. On consolidated basis, it has achieved revenue of ₹ 30,513.13 Lacs and PAT of ₹ 3,879.40 Lacs for the half year ended 30.09.2013.
- The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- Previous year's figures have been re-grouped/re-classified, whenever necessary, so as to make them comparable with the current year's figures.
- Statement of Assets and Liabilities:

Particulars	As at	
	30.09.2013	31.03.2013
	UNAUDITED	AUDITED
<b>A</b>		
<b>EQUITY AND LIABILITIES</b>		
1		
(a) Shareholders' funds		
(b) Share capital	5,203.07	5,203.07
(c) Reserves and surplus	9,253.03	5,794.56
(c) Money received against share warrants	-	-
Sub-total-Shareholders' funds	14,456.10	10,997.63
2		
(a) Non-current liabilities		
(b) Long-term borrowings	654.64	787.88
(b) Deferred tax liabilities (Net)	222.13	222.13
Sub-total - Non-current liabilities	876.77	1,009.81
3		
(a) Current liabilities		
(b) Short-term borrowings	7,493.50	7,531.23
(b) Trade payables	3,632.64	2,985.94
(c) Other current liabilities	4,624.30	7,505.16
(d) Short-term provisions	398.73	994.99
Sub-total-Current liabilities	18,087.17	19,017.32
<b>TOTAL-EQUITY AND LIABILITIES</b>	<b>31,420.04</b>	<b>31,024.76</b>
<b>B</b>		
<b>ASSETS</b>		
1		
(a) Non-current assets		
(a) Fixed assets	7,004.82	7,285.45
(b) Non-current Investments	6,761.64	6,761.64
(c) Long-term loans and advances	119.25	120.22
Sub-total - Non-current assets	13,885.71	14,167.31
2		
(a) Current assets		
(a) Inventories	5,360.18	5,131.76
(b) Trade receivables	10,817.17	9,141.88
(c) Cash and cash equivalents	642.85	41.30
(d) Short-term loans and advances	714.13	2,542.51
(e) Other current assets- Miscellaneous expenditure	-	-
Sub-total - Current assets	17,534.33	16,857.45
<b>TOTAL ASSETS</b>	<b>31,420.04</b>	<b>31,024.76</b>

₹ In Lakhs

For MARKSANS PHARMA LIMITED

MARK SILDANHA  
Managing Director



Place: Mumbai.  
Date: 31.10.2013  
www.marksanspharma.com